Aberrant Keap1 methylation in breast cancer and association with clinicopathological features
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Keap1 (Kelch-like ECH-associated protein 1) is an adaptor protein that mediates the ubiquitination/degradation of genes regulating cell survival and apoptosis under oxidative stress conditions. We determined methylation status of the KEAP1 promoter in 102 primary breast cancers, 14 pre-invasive lesions, 38 paired normal breast tissues and 6 normal breast from reductive mammoplasty by quantitative methylation specific PCR (QMSP). Aberrant promoter methylation was detected in 52 out of the 102 primary breast cancer cases (51%) and 10 out of 14 pre-invasive lesions (71%). No mutations of the KEAP1 gene were identified in the 20 breast cancer cases analyzed by fluorescence based direct sequencing. Methylation was more frequent in the subgroup of patients identified as ER positive-HER2 negative tumors (66.7%) as compared with triple-negative breast cancers (35%) (p = 0.05, Chi-square test). The impact of the interactions between Er, PgR, Her2 expression and KEAP1 methylation on mortality was investigated by RECPAM multivariable statistical analysis, identifying four prognostic classes at different mortality risks. Triple-negative breast cancer patients with KEAP1 methylation had higher mortality risk than patients without triple-negative breast cancer (HR = 14.73, 95%CI: 3.65-59.37). Both univariable and multivariable COX regressions analyses showed that KEAP1 methylation was associated with a better progression free survival in patients treated with epirubicin/cyclophosfamide and docetaxel as sequential chemotherapy (HR = 0.082; 95%CI: 0.007-0.934). These results indicate that aberrant promoter methylation of the KEAP1 gene is involved in breast cancerogenesis. In addition, identifying patients with KEAP1 epigenetic abnormalities may contribute to disease progression prediction in breast cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630 · cited 1×
“Keap1 possesses a dual role because it is able to sense a disturbance in the redox homeostasis and switch on and off its well-known substrate, Nrf2 (nuclear factor-erythroid 2-related factor 2) transcription factor.(1-4) Under physiological conditions, Nrf2 is retained in the cytoplasm by the binding with Keap1 and it…”
BackgroundDysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060 · cited 5×
“cell lung cancer (NSCLC).(6-8) Indeed, recent studies suggest that Keap1 may regulate several cellular pathways deeply involved in carcinogenesis.”
BackgroundInfluentialStructural basis for defects of Keap1 activity provoked by its point mutations in lung cancer
Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735 · cited 5×
“cell lung cancer (NSCLC).(6-8) Indeed, recent studies suggest that Keap1 may regulate several cellular pathways deeply involved in carcinogenesis.”
BackgroundInfluentialKEAP1 E3 Ligase-Mediated Downregulation of NF-κB Signaling by Targeting IKKβ
Lee, D.-F., Kuo, H.-P., Liu, M., Chou, C.-K., Xia, W., Du, Y., Shen, J., Chen, C.-T., Huo, L., Hsu, M.-C., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.07.025 · Cited by 399 · cited 2×
“One of the Keap1 substrates for ubiquitination is Ikkβ which upregulates the Nf-κB transcription factor through the negative regulation of its inhibitor Ikbα.(9) Under oxidative stress, Ikkβ is released from Keap1, and mediates the activation of Nf-kB regulated genes, resulting in increased growth, proliferation and a…”
BackgroundHigh Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer
Jiang, T., Chen, N., Zhao, F., Wang, X.-J., Kong, B., Zheng, W., & Zhang, D. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0713 · Cited by 286
A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity
Nioi, P., & Nguyen, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.051 · Cited by 212
Karihtala, P., Kauppila, S., Soini, Y., & Arja-Jukkola-Vuorinen (2011) · BMC Cancer · doi:10.1186/1471-2407-11-262 · Cited by 87
Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer
Takahashi, T., Sonobe, M., Menju, T., Nakayama, E., Mino, N., Iwakiri, S., Nagai, S., Sato, K., Miyahara, R., Okubo, K., et al. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21520 · Cited by 78
Cited by
The Nrf2 regulatory network provides an interface between redox and intermediary metabolism
Hayes, J. D., & Dinkova-Kostova, A. T. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.002 · Cited by 2,141
Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets
Park, J. H., Pyun, W. Y., & Park, H. W. (2020) · Cells · doi:10.3390/cells9102308 · Cited by 548
Modulating NRF2 in Disease: Timing Is Everything
Dodson, M., de la Vega, M. R., Cholanians, A. B., Schmidlin, C. J., Chapman, E., & Zhang, D. D. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021856 · Cited by 522
Ubiquitin ligases in oncogenic transformation and cancer therapy
Senft, D., Qi, J., & Ronai, Z. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.105 · Cited by 489
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival
Gorrini, C., Baniasadi, P. S., Harris, I. S., Silvester, J., Inoue, S., Snow, B., Joshi, P. A., Wakeham, A., Molyneux, S. D., Martin, B., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121337 · Cited by 289
Metadata
- Authors
- Barbano, R., Muscarella, L. A., Pasculli, B., Valori, V. M., Fontana, A., Coco, M., la Torre, A., Balsamo, T., Poeta, M. L., Marangi, G. F., Maiello, E., Castelvetere, M., Pellegrini, F., Murgo, R., Fazio, V. M., & Parrella, P.
- Venue
- Epigenetics
- Publisher
- Informa UK Limited
- Published
- 2013-01
- Volume
- 8
- Issue
- 1
- Pages
- 105-112
- ISSN
- 1559-2294 (ISSN-L)
- 1559-2308
- OpenAlex
- W1976441209
- Cited by
- 92
- References
- 9
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. https://app.cochat.ai/papers/10.4161/epi.23319
- The paper
- Barbano, R., Muscarella, L. A., Pasculli, B., Valori, V. M., Fontana, A., Coco, M., la Torre, A., Balsamo, T., Poeta, M. L., Marangi, G. F., Maiello, E., Castelvetere, M., Pellegrini, F., Murgo, R., Fazio, V. M., & Parrella, P. (2013). Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics. https://doi.org/10.4161/epi.23319
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.